A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Public ClinicalTrials.gov record NCT02207231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
Study identification
- NCT ID
- NCT02207231
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 837 participants
Conditions and interventions
Conditions
Interventions
- Guselkumab 100 mg Drug
- Placebo for guselkumab Drug
- Adalimumab Drug
- Placebo for adalimumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 26, 2014 (Actual)
- Primary completion
- Sep 29, 2015 (Actual)
- Completion
- Jun 17, 2020 (Actual)
- Last update posted
- Jul 23, 2021
2014 – 2020
United States locations
- U.S. sites
- 26
- U.S. states
- 18
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | San Francisco | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Farmington | Connecticut | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | Coral Gables | Florida | — | — |
| Not listed | Ocala | Florida | — | — |
| Not listed | Alpharetta | Georgia | — | — |
| Not listed | Rolling Meadows | Illinois | — | — |
| Not listed | Plainfield | Indiana | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Troy | Michigan | — | — |
| Not listed | New Brighton | Minnesota | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | East Windsor | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Johnston | Rhode Island | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Webster | Texas | — | — |
| Not listed | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02207231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 23, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02207231 live on ClinicalTrials.gov.